Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabis-based therapeutics - Skye Bioscience

Next Previous
Drug Profile

Research programme: cannabis-based therapeutics - Skye Bioscience

Alternative Names: Cannabidiol derivatives - Skye Bioscience; Cannabidiol Valine Hemisuccinate; cannabidiol ­valine hemisuccinate; Cannabinoid cocktail - Skye Bioscience; Cannabionoid therapeutics - Skye Bioscience; CBD derivatives - Skye Bioscience; CBGA-Q; CBGA-Q-Na Salt; CBGAquinone; NB 1222; NB 2111; NB 2221; NB 2222; NB 23R1; NB 3111; NB 31R1; NB 51R1; NB3000 series; THC-valine-hemisuccinate; UM 5070

Latest Information Update: 20 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NEMUS Bioscience; University of Mississippi
  • Developer Skye Bioscience; University of Mississippi
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antibacterials; Antiepileptic drugs; Antifibrotics; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Eye disorder therapies; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Infections
  • No development reported Anxiety disorders; Chemotherapy-induced nausea and vomiting; Diabetic retinopathy; Dry eyes; Epilepsy; Macular degeneration; Methicillin-resistant Staphylococcus aureus infections; Muscle spasticity; Open-angle glaucoma; Pain; Peripheral nervous system diseases; Uveitis

Most Recent Events

  • 08 Jan 2022 Skye Bioscience terminates its licence agreement with University of Mississippi for cannabis-based therapeutics
  • 12 Oct 2021 Skye Bioscience and VivaCell Biotechnology Espana (Emerald Health Biotechnology Espana) collaborate to discover and develop novel cannabinoids
  • 29 Jun 2021 Early research in Infections in USA (unspecified route), prior to June 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top